mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques.

[1]  Manxiang Li,et al.  Knockdown of mTOR by lentivirus‑mediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein E‑deficient mice. , 2013, International journal of molecular medicine.

[2]  G. Santulli,et al.  Tailoring mTOR-based therapy: molecular evidence and clinical challenges. , 2013, Pharmacogenomics.

[3]  E. Mercken,et al.  Metformin improves healthspan and lifespan in mice , 2013, Nature Communications.

[4]  T. Herbert,et al.  Evidence for Rapamycin Toxicity in Pancreatic β-Cells and a Review of the Underlying Molecular Mechanisms , 2013, Diabetes.

[5]  K. Boini,et al.  Enhancement of Autophagy by Simvastatin through Inhibition of Rac1-mTOR Signaling Pathway in Coronary Arterial Myocytes , 2013, Cellular Physiology and Biochemistry.

[6]  G. Tarantino,et al.  Inhibition of the mTOR pathway: A possible protective role in coronary artery disease , 2013, Annals of medicine.

[7]  D. Sabatini,et al.  Regulation of mTORC1 and its impact on gene expression at a glance , 2013, Journal of Cell Science.

[8]  Daniel J. Lightell,et al.  Relative resistance to Mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors. , 2013, The Ochsner journal.

[9]  N. Pallet,et al.  Adverse events associated with mTOR inhibitors , 2013, Expert opinion on drug safety.

[10]  I. Palacios,et al.  Randomized comparison of cost‐saving and effectiveness of oral rapamycin plus bare‐metal stents with drug‐eluting stents: Three‐year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[11]  Patrick W Serruys,et al.  Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives , 2012, Expert review of medical devices.

[12]  D. Teupser,et al.  Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice. , 2012, Atherosclerosis.

[13]  D. Alessi,et al.  Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. , 2012, Gastroenterology.

[14]  D. Schrijvers,et al.  Everolimus Triggers Cytokine Release by Macrophages: Rationale for Stents Eluting Everolimus and a Glucocorticoid , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[15]  D. Accili,et al.  Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. , 2012, The Journal of clinical investigation.

[16]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[17]  Dudley Lamming,et al.  Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity , 2012, Science.

[18]  Jessica L. Grimsby,et al.  Antirestenotic Mechanisms of Everolimus on Human Coronary Artery Smooth Muscle Cells: Inhibition of Human Coronary Artery Smooth Muscle Cell Proliferation, but not Migration , 2012, Journal of cardiovascular pharmacology.

[19]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[20]  K. Shokat,et al.  The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile , 2011, Proceedings of the National Academy of Sciences.

[21]  I. Ben-Sahra,et al.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. , 2011, Cancer research.

[22]  Z. Varghese,et al.  Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. , 2010, American journal of physiology. Heart and circulatory physiology.

[23]  B. Viollet,et al.  Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. , 2010, Cell metabolism.

[24]  Chang Hwa Jung,et al.  mTOR regulation of autophagy , 2010, FEBS letters.

[25]  K. Robinson,et al.  Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. , 2009, EuroIntervention.

[26]  B. Nogueira,et al.  Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice. , 2009, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[27]  K. Yamashita,et al.  The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. , 2009, The American journal of pathology.

[28]  Patrick W Serruys,et al.  A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods , 2009, The Lancet.

[29]  D. Praticò,et al.  Low‐dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor , 2009, British journal of pharmacology.

[30]  Yun Zhang,et al.  Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels , 2009, British journal of pharmacology.

[31]  A. Corsini,et al.  Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits , 2009, Journal of Pharmacology and Experimental Therapeutics.

[32]  Kenneth L. Hensley,et al.  Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice , 2008, Aging cell.

[33]  M. Pfisterer,et al.  Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis , 2008, BMJ : British Medical Journal.

[34]  D. Teupser,et al.  Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. , 2008, Atherosclerosis.

[35]  P. Serruys,et al.  Rapamycin modulates the eNOS vs. shear stress relationship. , 2008, Cardiovascular research.

[36]  P. V. van Diest,et al.  HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. , 2007, Atherosclerosis.

[37]  Christina K. Chan,et al.  Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. , 2007, Atherosclerosis.

[38]  Z. Varghese,et al.  Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. , 2007, American journal of physiology. Heart and circulatory physiology.

[39]  G. D. De Meyer,et al.  Selective Clearance of Macrophages in Atherosclerotic Plaques by the Protein Synthesis Inhibitor Cycloheximide , 2007, Journal of Pharmacology and Experimental Therapeutics.

[40]  G. D. De Meyer,et al.  Selective clearance of macrophages in atherosclerotic plaques by autophagy. , 2007, Journal of the American College of Cardiology.

[41]  J. Shyy,et al.  Statins Activate AMP-Activated Protein Kinase In Vitro and In Vivo , 2006, Circulation.

[42]  Ramkumar Veppathur Mohan,et al.  mTOR Inhibition Induces Endothelial Progenitor Cell Death , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[43]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[44]  I. Palacios,et al.  Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. , 2006, Journal of the American College of Cardiology.

[45]  C. Beaumont,et al.  Anemia after Late Introduction of Sirolimus May Correlate with Biochemical Evidence of a Chronic Inflammatory State , 2005, Transplantation.

[46]  R. Pakala,et al.  Rapamycin Attenuates Atherosclerotic Plaque Progression in Apolipoprotein E Knockout Mice: Inhibitory Effect on Monocyte Chemotaxis , 2005, Journal of cardiovascular pharmacology.

[47]  P. Rychahou,et al.  Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. , 2005, Transplantation proceedings.

[48]  G. Thomas,et al.  Disruption of the Mouse mTOR Gene Leads to Early Postimplantation Lethality and Prohibits Embryonic Stem Cell Development , 2004, Molecular and Cellular Biology.

[49]  D. Fingar,et al.  The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. , 2004, American journal of physiology. Cell physiology.

[50]  P. Nambi,et al.  Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. , 2003, Transplantation proceedings.

[51]  S. Adelman,et al.  Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E‐Deficient Mice , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  Mark M. Kockx,et al.  Phagocytosis and Macrophage Activation Associated With Hemorrhagic Microvessels in Human Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[53]  Christine C. Hudson,et al.  Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.

[54]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[55]  C. Ballantyne,et al.  Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. , 2001, Transplantation.

[56]  J. Correas,et al.  CHARACTERISTICS OF SIROLIMUS-ASSOCIATED INTERSTITIAL PNEUMONITIS IN RENAL TRANSPLANT PATIENTS , 2001, Transplantation.

[57]  J. Cristol,et al.  Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. , 2000, Transplantation proceedings.

[58]  C. Groth,et al.  Pharmacokinetics and Safety of Single Oral Doses of Sirolimus (Rapamycin) in Healthy Male Volunteers , 2000, Therapeutic drug monitoring.

[59]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[60]  S. Marx,et al.  Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. , 1995, Circulation research.

[61]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[62]  Dolors Soy-Muner,et al.  Neumonitis intersticial como reacción adversa a inhibidores de mTOR , 2013 .

[63]  Erasmus Mc,et al.  New Revolution in Vascular Interventional Medicine: Bioresorbable Scaffolds for Atheroregression , 2013 .

[64]  T. Lüscher,et al.  Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. , 2010, European heart journal.

[65]  Fei Li,et al.  Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells. , 2010, Texas Heart Institute journal.

[66]  G. Friedman,et al.  The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors. , 2007, Journal of pharmaceutical sciences.

[67]  F. Sánchez‐Madrid,et al.  Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. , 2004, Atherosclerosis.

[68]  K. Resch,et al.  Everolimus/Cyclosporine Interactions on Bile Flow and Biliary Excretion of Bile Salts and Cholesterol in Rats , 2004, Digestive Diseases and Sciences.

[69]  M. Burnett,et al.  Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. , 2003, Cardiovascular radiation medicine.